View meeting's sessions and poster gallery
Not able to attend the HBV endpoints meeting in London?
You can now tune in to view sessions you have missed or want to review.
Scientific Organising Committee
- Prof. Markus Cornberg, Germany
- Prof. Anna Lok, United States
- Prof. Norah Terrault, United States
- Prof. Fabien Zoulim, France
The purpose of this workshop is to bring together the academic, regulatory and pharmaceutical (diagnostic and therapeutic) communities to discuss therapeutic endpoints, trial designs, appropriate patient populations and safety concerns with regards to novel therapeutic approaches aimed to achieve HBV cure. This meeting will bring all the stakeholders together to discuss definitions of HBV cure, likelihood of HBV cure with currently approved therapies, preclinical and clinical data on novel antiviral and immune modulatory therapies, appropriate designs and endpoints for trials to evaluate therapies aimed at HBV and HDV cure, and strategies to efficiently and safely evaluate combination therapies. These discussions will provide guidance regarding potential pathways leading to regulatory approval of therapies that will result in high rates of HBV cure in individuals with chronic hepatitis B and chronic hepatitis D.
Abstract submission now closed
Discover the latest research on HBV endpoints.
For anything you need to know about submission process, dates and presenter guidelines, download the abstract information document.
EASL has prepared an abstract submission checklist to guide you through your submission.
For anything you need to know about venue, your accommodation and booking process, download the Get Ready information document
EASL has negotiated special rates for conference delegates at the Novotel London Excel, however, the number of rooms to be booked is limited. We therefore recommend to book your accommodation early.
EASL welcomes the interest of the media in matters relating to hepatology and is happy to provide assistance to journalists who wish to attend the EASL-AASLD HBV Endpoints meeting held in London, United Kingdom.
Registered press representatives will have access to all sessions including the Exhibition.
Please contact EASL Press Office with any questions regarding media, press registration, audio or video recording.
Should you have any question about the event, your registration or accommodation, please contact EASL-AASLD@easloffice.eu
“The EASL-AASLD HBV ENDPOINTS, London, United Kingdom, 08/03/2019-09/03/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”
“Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be
found at www.ama-assn.org/education/earn-credit-participation-international-activities.
“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.
In order to help you issue individual certificates to each participants, please find below the breakdown of ECMEC®s per day:
08.03.2019 – 8.00
09.03.2019 – 3.00
The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.
It is estimated that 2 billion people are infected with hepatitis B virus (HBV) globally, with 686,000 people dying from complications of the disease each year.
While the development of nucleos(t)ide analogues (NAs) has led to vast improvements in the care of patients with chronic HBV infection (… read full article)
The HBV endpoints meeting is kindly supported by